Long-term Treatment with Galcanezumab in 29 Patients with Chronic Migraine: Results from the 3-year Continued Access Program of the REGAIN Study

Authors
Category Primary study
JournalNeurology
Year 2022
This article has no abstract
Epistemonikos ID: 8f5ab1cb52c68c3b3c4f2ebb53b3545522cfd265
First added on: Feb 14, 2025